JD Supra December 21, 2021
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking
Dealmaking within the pharma, medical and biotech sector continued from its promising start to the year. Following robust activity throughout the year, Q1-Q3 deal value has already overtaken all annual totals on record except 2019, with three months of dealmaking left to record for the year.
M&A activity by value 2006 – 2021 [YTD]
Target location: Global Bidder location: Global Sectors: Pharma, medical and biotech
Interest in deals within the top end of the market has reached a new high. A total of 16 deals were announced in Q1-Q3 2021 with a price tag of over US$5 billion—the highest...
Today's Sponsors
Today's Sponsor